Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

NCT01684163 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

369

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: GLYX-13 5 mg/kg
DRUG: GLYX-13 10 mg/kg
DRUG: Placebo

Sponsor

Naurex, Inc, an affiliate of Allergan plc